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Abstract
Background: Influenza vaccines are recommended for administration by the intramuscular route.
However, many physicians use the subcutaneous route for patients receiving an oral anticoagulant because
this route is thought to induce fewer hemorrhagic side effects. Our aim is to assess the safety of
intramuscular administration of influenza vaccine in patients on oral anticoagulation therapy.
Methods: Design: Randomised, controlled, single blinded, multi-centre clinical trial. Setting: 4 primary
care practices in Barcelona, Spain. Participants: 229 patients on oral anticoagulation therapy eligible for
influenza vaccine during the 2003–2004 season. Interventions: intramuscular administration of influenza
vaccine in the experimental group (129 patients) compared to subcutaneous administration in the control
group (100 patients). Primary outcome: change in the circumference of the arm at the site of injection at
24 hours. Secondary outcomes: appearance of local reactions and pain at 24 hours and at 10 days; change
in INR (International Normalized Ratio) at 24 hours and at 10 days. Analysis was by intention to treat using
the 95% confidence intervals of the proportions or mean differences.
Results: Baseline variables in the two groups were similar. No major side effects or major haemorrhage
during the follow-up period were reported. No significant differences were observed in the primary
outcome between the two groups. The appearance of local adverse reactions was more frequent in the
subcutaneous administration group (37,4% vs. 17,4%, 95% confidence interval of the difference 8,2% to
31,8%).
Conclusion: This study shows that the intramuscular administration route of influenza vaccine in patients
on anticoagulant therapy does not have more side effects than the subcutaneous administration route.
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Influenza vaccines are recommended for administration
by the intramuscular route [1]. These recommendations
are based on similar immunogenicity but less reactogenity
if administered intramuscularly than subcutaneously or
intradermally [2,3].
However, many physicians use the subcutaneous route for
patients receiving an oral anticoagulant therapy because
this route is thought to induce fewer hemorrhagic side
effects, although no clinical trials support this recommen-
dation. The number of people receiving oral anticoagu-
lant therapy has increased over the past years as a result of
a greater number of its indications; more people in this
group are therefore likely to meet eligibility criteria for the
influenza vaccination.
There is currently insufficient evidence to recommend the
subcutaneous route in these patients. One before-after
study [4](2) with 36 patients receiving warfarin showed
no differences in the circumference of the arm compared
to baseline. Only two randomised clinical trials have
assessed the safety of the route of administration of influ-
enza vaccine in patients receiving oral anticoagulant ther-
apy [5,6]. Although both had small sample sizes (26 and
59), they seemed to support the safety of the intramuscu-
lar route.
Moreover, the US Centers for Disease Control and Preven-
tion recommends [7] that influenza vaccine should be
administered intramuscularly even in those patients
receiving oral anticoagulant therapy, provided the doctor
considers it appropriate and safe. After administration,
compression at the point of injection should be applied
for at least 2 minutes. This recommendation is based on a
study carried out in 153 haemophilic patients vaccinated
against hepatitis B [8].
To address this question, we studied the safety of the intra-
muscular route of administration for influenza vaccine
compared to subcutaneous administration in patients
receiving oral anticoagulation therapy.
Methods
Objective and design
We conducted a randomised, single blinded controlled
clinical trial to assess the safety of the intramuscular
administration of influenza vaccine in patients on oral
anticoagulation therapy.
Study population
We carried out the study in four primary care practices in
Barcelona (Spain) between October and December 2003.
Eligible patients were those older than 18 who were being
treated with acenocoumarol or warfarin and were eligible
for influenza vaccination. Patients with an INR higher
than 4 at the time of enrolment or in the last two months,
with a history of major bleeding, known hypersensitivity
to any of the vaccine's components or diagnosed with
dementia were excluded. We identified eligible patients
through a computerized clinical registry search.
Intervention
The control group received one dose of the Mutagrip® 0,5
ml of the 2003–2004 formulation of influenza vaccine
through a preloaded syringe with a needle of 16 mm (5/8
inches) in length and 0,5 mm (25-gauge) in diameter sub-
cutaneously in the deltoid region. The intervention group
received the same vaccine using the same needle and
syringe combination in the same place but intramuscu-
larly. The vaccine was administered in the patient's own
practice by specifically trained health care professionals.
Ethical approval
Approved by the IDIAP Jordi Gol ethics committee of the
Insitut Català de la Salut.
Randomisation and blinding
We randomised patients to either the subcutaneous or
intramuscular administration group. The randomisation
of patients to each group was based on a computer gener-
ated list. After obtaining written informed consent from
eligible patients and collecting baseline data the patient
was assigned to either group.
Health care professionals administering the vaccine could
not be blinded to patients' allocation at baseline. Blinding
of the professional collecting follow-up data reduced
potential bias. Since patients were not informed of the
route of administration, we considered them blinded to
the intervention as well.
Follow up and outcome assessment
We carried out three follow up visits: the first at the
moment of vaccination, the second at 24 hours and the
third at 10 days. The visits took place in the patients' own
practices and were carried out by health care professionals
from their practice. When a patient failed to attend a visit,
three attempts were made to contact him/her by tele-
phone at different times. If they declined a request to
come to the missed visit, they were asked for the reason
and if they had had any side effects.
The outcome variables were: a) presence of any major side
effect. b) Change in the circumference of the arm at the
point of injection to detect haemorrhage or haematoma.
A measure specifically designed for the study was used to
locate the point of the circumferential reading, which cor-
responded to the point of injection on the deltoid area.
One end of the measure, which would run parallel to thePage 2 of 7
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external border of the epicondyle with the elbow flexed to
90°; the other end of the measure would show the circum-
ference reading point. An increase of the circumference of
the arm of one or more centimetres at 24 hours after the
administration of the vaccine was considered clinically
significant; c) presence of skin lesions at the point of injec-
tion at 24 hours and after 10 days; d) the existence of pain
during the first 24 hours and after 10 days, measured with
a visual analog pain scale (from zero to ten); e) the capil-
lary blood INR was measured with Coagucheck® at 24
hours and at 10 days to assess the interaction between the
anticoagulant treatment and the vaccination.
Sample size and data analysis
The sample size calculation was based on hypothesis test-
ing to establish the difference between the subcutaneous
and intramuscular administration groups in the propor-
tion of patients with an increase of the circumference of
the arm equal or higher than one centimetre. From a pre-
vious study [6] we established that the expected event rate
in the subcutaneous administration group was 40%. The
intramuscular administration group should not differ
from this 40% by more than 50% (20%). An α = 0.05 and
β = 0.20 were used. This resulted in a sample size require-
ment of 97 patients per group. All patients meeting the
inclusion criteria from the four practices were invited to
participate in the study.
Analysis was by intention to treat since each patient was
analysed in his allocation group. However, only patients
who completed all follow-up visits were included in the
analysis, because we could not compute the outcome var-
iables with the rest. We carried out a descriptive analysis
of the baseline and follow-up data. For the categorical out-
come variables, the 95% confidence intervals of the pro-
portions difference between the two groups of the study
through the statistic z was computed after checking the
application conditions. We computed, for the continuous
outcome variables, the 95% confidence interval of the
means difference between the two groups through a t-test
after checking the application conditions. In both cases,
we rejected the null hypothesis of no difference when the
confidence interval included the 0 value. The relative risk
and number needed to harm were used as association and
impact measures.
Subsequently, we made a sub-analysis to compare
patients with a baseline INR lower than 2,5 against those
equal or higher than 2,5 only for the intramuscular group.
The same statistical methods were used as those in the
main analysis.
All calculations were made with the statistical system 'R'
[9].
Results
Three hundred ninety-nine patients were assessed for eli-
gibility. One hundred seventy of them were excluded (Fig-
ure 1) for the following reasons: not meeting inclusion
criteria (15 had been already vaccinated; 1 was not on
anticoagulation therapy); meeting exclusion criteria (16
had an INR > 4, 4 had a diagnose of dementia, 1 had had
a previous major bleeding, 1 was allergic to a vaccine com-
ponent); refused to be vaccinated (47); or refused to par-
ticipate in the study (85).
Two hundred twenty-nine patients were randomised and
participated in the study (129 in the subcutaneous group
and 100 in the intramuscular group). Participation rates
in the practices were 70/89, 56/112, 43/102 and 60/96.
All patients received the intervention to which they had
been allocated.
No clinically important differences in the baseline varia-
bles were observed between the groups at the time of
enrolment. Data collected from patients who refused to
participate in the study did not suggest to be a subgroup
with special characteristics (Table 1).
Most patients were taking acenocoumarol (225/229), and
the rest were taking warfarin (4/229). The main diagnoses
were atrial fibrillation (160/229), valvular heart disease
(39/229) and ischemic heart disease (28/229). 19
patients receiving anticoagulant treatment had a metal
prosthetic heart valve, so they had a higher therapeutic
INR goal (2,5–3,5) as compared to the rest (2–3).
Three patients failed to attend the 24 hour visit and a fur-
ther 19 the 10th day visit. Of the patients lost to follow up,
14 belonged to the subcutaneous administration group
and 8 to the intramuscular group. All of them were con-
tacted by telephone but refused to come to the follow-up
visits. Follow-up variables were analyzed in 207 patients,
115 in the subcutaneous administration group and 92 in
the intramuscular administration group. The baseline
data of patients lost during the follow up, suggests it is a
younger subgroup (Table 1).
None of the patients reported major side effects in any of
the two follow-up visits, included those who failed the
follow-up visits.
The circumference of the arm after 24 hours tended to
increase in both groups (Table 2). Around 20% of patients
in both groups had an increase of the circumference of the
arm higher than one centimetre. No statistically signifi-
cant differences between the groups were observed.
No patients had skin lesions in the area of injection before
the vaccination. The appearance of skin lesions after 24Page 3 of 7
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observed in 43/115 (37,4%) patients in the subcutaneous
administration group and 16/92 (17,4%) patients in the
intramuscular administration group. This difference was
statistically significant (95% confidence interval of the
difference: 8,2% to 31,8%), representing a relative risk of
2,14 (Confidence Interval of 95% 1,30 – 3,56) and a
Number Needed to Harm of 5,0 (Confidence Interval of
95% 3,1 to 11,3). The most frequent lesion observed was
erythema, which appeared in 36/115 (31,3%) of the
patients of the subcutaneous administration group and in
8/92 (8,7%) in the intramuscular administration group.
This was followed by plaque and pruritus. Three patients
presented haematoma (2 in the subcutaneous administra-
tion group and 1 in the intramuscular administration
group); all of them with a basal INR between 2 and 3. All
local reactions had disappeared by the 10th day after the
vaccination.
Patients in the subcutaneous administration group pre-
sented higher scores in the pain scale 24 hours after vacci-
nation (Table 2), although the mean difference was not
statistically significant. A higher percentage of patients in
this group marked a value other than zero in the scale,
although the scores did not differ significantly to those
from the intramuscular administration group. No patient
reported pain at the area of the injection by the 10th day.
Flow chartigure 1
Flow chart
 
Assessed for 
eligibility (n=399) 
Randomised (n=229)
Excluded (n=170) 
     Not meeting inclusion criteria (n=16) 
     Meeting exclusion criteria (n=22) 
     Refused to be vaccinated (n=47)       
     Refused to participate (n=85) 
Allocated to experimental/intramuscular 
group (n=100) 
 
Received allocated intervention (n=100) 
Do not receive allocated intervention; 
give reasons (n=0) 
Allocated to control/subcutaneous group 
(n=129) 
 
Received allocated intervention (n=129) 
Do not receive allocated intervention; 
give reasons (n=0) 
Lost of follow-up: 
    Visit 24h: n=0 
    Visit 10d: n=8 (refused to follow up) 
 
Lost of follow-up: 
Visit 24h: n=3 (2 refused to follow up     
and 1 personal reasons) 
    Visit 10d: n=11 (refused to follow up) 
 
Analysed: n=92 
Excluded from analysis: n=0 
Analysed: n=115
Excluded from analysis: n=0  Page 4 of 7
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24 hours in the subcutaneous administration group and
to decrease in the intramuscular administration group,
although the difference did not reach statistical signifi-
cance. This differential behaviour did not exist the 10th
day after the vaccination, since in both groups an increase
of the baseline INR was seen.
No differences in any of the outcome variables were found
between patients with baseline INR lower and higher than
2.5 within the intramuscular administration group (Table
3).
Discussion
Our study demonstrates the absence of clinically signifi-
cant haemorrhaging following intramuscular administra-
tion of influenza vaccine in patients receiving
anticoagulation therapy. Furthermore, the appearance of
local lesions was significantly more frequent in patients
vaccinated subcutaneously. These data appear to confirm
Table 1: Baseline data
Subcutaneous group 
(n = 129)
Intramuscular group 
(n = 100)
Refuse to participate 
(n = 132)
Lost of follow-up 
(n = 22)
Mean age (SD), years 73,5 (9,7) 73,7 (9,2) 73,5 (11,0) 66,2 (17,1)
Men, n (%) 81 (62,8%) 56 (56,0%) 78 (59,1%) 12 (54,5%)
Therapeutical objective, n (%)
INR 2,0 – 3,0 116 (89,9%) 94 (94,0) 128 (97,0%) 21 (95,5%)
INR 2,5 – 3,5 13 (10,1%) 6 (6,0%) 4 (3,0%) 1 (4,5%)
Mean INR (SD) 2,25 (0,59) 2,37 (0,56) 2,40 (0,61)
INR, n (%)
INR < 2 42 (32,6%) 23 (23,0%) 5 (22,7%)
INR >= 2 & < 3 73 (56,6%) 63 (63,0%) 13 (59,1%)
INR >= 3 & <= 4 14 (10,9%) 14 (14,0%) 4 (18,2%)
Mean arm circumference (SD), cm 32,1 (3,5) 31,8 (4,1) 32,5 (4,2)
Table 2: Follow-up data
Subcutaneous group (n = 115) Intramuscular group (n = 92) 95% confidence interval of the 
difference
Mean circumference of the arm (SD), cm, 24 h 32,1 (3,4) 32,2 (4,2)
Mean change circumference of the arm (SD), cm, 
24 h
+0,20 (1,44) +0,28 (0,91) -0,40 to +0,25 *
Patients with increase of the circumference of the 
arm >= 1 cm, n (%), 24 h
27 (23,5%) 18 (19,6%) -7,3% to +15,1%
Patients with skin lesions in the administration 
area, n (%), 24 h
43 (37,4%) 16 (17,4%) +8,2% to +31,8%
Erythema, n 36 8
Papule, n 0 3
Plaque, n 7 5
Nodule, n 0 2
Cyst, n 0 0
Vesicle, n 0 0
Blister, n 0 0
Ulcer, n 0 0
Scab, n 0 2
Haematoma, n 2 1
Pruritus, n 4 2
Insensitivity, n 1 0
Mean Visual Analog Pain Scale (SD), 24 h 0,43 (1,08) 0,29 (0,84) -0,12 to 0,41 *
Patients with Visual Analog Pain Scale > 0, n (%), 
24 h
23 (20,0%) 13 (14,1%) -4,3% to +16,1%
Mean INR (SD), 24 h 2,28 (0,64) 2,30 (0,70)
Mean change INR (SD), 24 h +0,04 (0,50) -0,06 (0,55) -0,04 to +0,25 *
Mean INR (SD), 10d 2,31 (0,67) 2,44 (0,95)
Mean change INR (SD), 10d +0,08 (0,79) +0,07 (0,93) -0,24 to +0,24 *
*Calculated under the checked assumption of variance homogeneity of both samples.Page 5 of 7
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effects than the subcutaneous route.
As a consequence of an increased number of indications
for anticoagulant therapy, the number of patients receiv-
ing this treatment is increasing. This has moved patient
management away from the exclusivity of certain specific
services to primary care practices which makes it a first
step towards a more effective and efficient management
achieved by the proper patient. At the same time, the fears
about possible risks, responsible for initial recommenda-
tions to avoid the intramuscular route, have been slowly
overcome, and a more realistic vision has emerged. In the
case of influenza vaccination, the use of a short needle
and small diameter minimizes the tissue damage due to
an intramuscular injection and it is fair to presume that it
should not infer a substantial risk of haemorrhage.
To date, this is the largest study of the safety of the intra-
muscular route of the influenza vaccine in patients on
anticoagulation therapy. A potential weakness is that we
do not know the sample needed to detect a major second-
ary effect with the intramuscular route. Nevertheless this
is also unknown for the subcutaneous route. One thing to
consider in further investigations is to include the comor-
bidity and other treatments in the analysis. Another weak-
ness is that twenty two patients were lost to follow-up,
although all were contacted by telephone and none
reported any event attributable to the intervention.
We can not generalize the results to other vaccines or to
intramuscular injections with needles of a greater calibre.
Of the most commonly used adult vaccines, tetanus tox-
oid and hepatitis B vaccine are marketed with needles of
25 mm long (1 inch) and 0,6 mm of diameter (23-gauge).
Pneumococcal vaccine has the same diameter as influenza
vaccine (0,5 mm or 25-gauge) but a greater length (25
mm). As noted in the introduction, safety data are only
available for hepatitis B vaccine, although this is based on
a study of haemophilic patients without a control group.
Although the sample size is small, the influenza vaccine
could be administered with safety to patients with artifi-
cial valves and higher INR levels (2,5 to 3,5), as we
observed the same results in the group of patients who at
the time of the vaccination had an INR between 2,5 and 4
and those who had INR lower than 2,5 (Table 3).
Our results suggest that administering influenza vaccine
intramuscularly in patients receiving anticoagulant ther-
apy can be done safely, and we would support changes in
recommendations to allow for intramuscular administra-
tion without compression at the site of injection. While
addressing similar issues regarding other vaccines, espe-
cially the tetanus vaccine, is still necessary, we believe that
intramuscular administration of influenza and hepatitis B
vaccines in this population is safe.
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